分红方面，药明康德A股上市后累计派现140.60亿元。近三年，累计派现104.06亿元。 机构持仓方面，截止2025年9月30日，药明康德十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2.49亿股，相比上期减少5260.71万股。华夏上证50ETF（510050）位居第七大流通股东， 持股4778.07万股，相比上期减少121.71万股。华泰柏瑞沪深300ETF（510300）位居第八大流通股东， 持股4268.15万股，相比上期减少188.65万股。中欧医疗健康混合A（003095）、易方达沪深300医药ETF （512010）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资金流向方面，主力资金净流出2.06亿元，特大单买入1.76亿元，占比9.25%，卖出3.35亿元，占比 17.58%；大单买入3.99亿元，占比20.91%，卖出4.46亿元，占比23.38%。 药明 ...

Core Insights - The top three companies with the highest short positions as of February 13 are COSCO Shipping Holdings (01919), CATL (03750), and Ping An Insurance (02318), with short ratios of 19.07%, 16.71%, and 15.47% respectively [1][2] Group 1: Companies with Highest Short Ratios - COSCO Shipping Holdings (01919) has a short position of 526 million shares, representing a short ratio of 19.07% [2] - CATL (03750) has a short position of 26.05 million shares, with a short ratio of 16.71% [2] - Ping An Insurance (02318) has a short position of 1.152 billion shares, reflecting a short ratio of 15.47% [2] - Dongfang Electric (01072) has a short position of 62.39 million shares, with a short ratio of 15.29% [2] - Sunny Optical Technology (02382) has a short position of 16.4 million shares, maintaining a short ratio of 15.17% [2] Group 2: Companies with Increased Short Positions - WuXi AppTec (02359) saw the largest increase in short ratio, rising by 2.66% to 12.45% [2][3] - Chifeng Jilong Gold Mining (06693) increased its short ratio by 1.63% to 3.60% [2][3] - Changfei Optical Fiber (06869) experienced a 1.55% increase in short ratio, reaching 4.13% [2][3] - Meitu (01357) had a short ratio increase of 1.38% to 8.00% [2][3] - Weimob (02013) saw a 1.33% increase in its short ratio, now at 12.16% [2][3] Group 3: Companies with Decreased Short Positions - Tianqi Lithium (09696) had the largest decrease in short ratio, dropping by 2.29% to 2.91% [3][4] - Vanke (02202) saw a reduction of 2.17% in its short ratio, now at 14.25% [3][4] - Jiangsu Ninhui Expressway (00177) decreased its short ratio by 1.02% to 10.61% [3][4] - Ganfeng Lithium (01772) experienced a decrease of 1.01% in its short ratio, now at 8.81% [3][4] - Country Garden (02007) saw a reduction of 0.91% in its short ratio, now at 1.02% [3][4]

| 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.315 | 2.25 | 757.14% | -50.71% | | 京城机电股份 | 4.380 | 14.1 | 285.62% | 12.60% | | (00187) | | | | | | 中石化油服(01033) | 1.010 | 3.22 | 282.18% | -2.51% | | 弘业期货(03678) | 3.190 | 9.96 | 273.98% | 2.61% | | 南京熊猫电子股份 | 5.280 | 14.78 | 235.23% | -0.03% | | (00553) | | | | | | 凯盛新能(01108) | 4.070 | 11.11 | 227.03% | 1.59% | | 钧达股份(02865) | 35.700 | 97.15 | 225.97% | -17.30% | | 复旦张江(01349) | 3.200 | 8.62 | 222.81% | -15.46% | | 安德利果 ...

五成公司预告盈利药明康德、三生国健等预盈超10亿 以业绩预告净利润下限统计，已公布2025年业绩预告的274家医药生物上市公司中，137家预计实现盈利，占比五成。 其中，10家公司预告归母净利润超10亿元，包括药明康德、三生国健、吉林敖东等。 新华财经北京2月24日电截至2026年2月12日，根据申万行业分类，A股医药生物行业逾500家上市公司，其中约274家已披露2025年业绩预告。 整体来看，已披露2025年业绩预告的274家医药生物上市公司中，业绩偏正面（包括预增、略增、扭亏及续盈）的企业合计90家。 137家医药生物上市公司2025年实现盈利，占比50%，其中10家归母净利润超10亿元。 图1：A股医药生物行业上市公司2025年业绩预告类型 图3：药明康德2025年度业绩预告 | | 2025年预告利润超过10亿元 | | | --- | --- | --- | | 证券代码 | 证券简称 | 业绩预告类型 | | 603259.SH | 药明康德 | 预增 | | 688336.CH | 三生国健 | 预增 | | 000623.SZ | 吉林敖东 | 预增 | | 688578.SH | 艾力斯 ...

智通财经APP获悉，截止2月23日收盘，东北电气(00042)、京城机电股份(00187)、弘业期货(03678)分列 AH溢价率前三位，溢价率分别为757.14%、280.60%、278.12%；宁德时代(03750)、药明康德(02359)、 招商银行(03968)分列AH溢价率末三位，溢价率分别为-18.31%、-7.13%、-5.36%。其中郑州银行 (06196)、龙蟠科技(02465)、剑桥科技(06166)的偏离值位居前三，分别为14.55%、11.57%、10.92%；另 外，东北电气(00042)、长飞光纤光缆(06869)、晨鸣纸业(01812)的偏离值位居后三，分别 为-51.17%、-48.00%、-45.02%。 | 南华期货股份 | | | | | | --- | --- | --- | --- | --- | | (02691) | | | | | | 弘业期货(03678) | 3.200 | 10.1 | 278.12% | 6.85% | | 中国中免(01880) | 91.850 | 97.1 | 26.63% | 6.70% | | 金隅集团(02009) | 0.8 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - In 2025, China's foreign trade showed strong resilience, with total exports reaching a historical high, growing by 5.5% year-on-year, despite a complex external environment [1][57] - China's trade surplus exceeded $1 trillion for the first time, marking a significant increase of 19.8% year-on-year [1][57] - The net export of goods and services contributed 1.64 percentage points to GDP growth, the second-highest level since 2007, only behind 2021 [3] Group 2 - The diversification of external demand has strengthened, with emerging markets compensating for the decline in exports to the US, which fell by 19.79% year-on-year [6] - Exports to ASEAN, Africa, and the Middle East saw significant growth rates of 25.9%, 13.64%, and 9.7% respectively, contributing positively to the overall export scale [6] - The share of US exports in China's total exports decreased by 3.53 percentage points to 11.15% [6] Group 3 - The product structure of China's foreign trade is shifting towards higher value chains, with high-end products like electrical machinery, machinery, automobiles, and ships being the main export drivers [8] - Traditional light industrial products such as furniture and toys have seen a decline in export scale due to tariff friction and industrial chain relocation [8] Group 4 - The restructuring of global supply chains is creating significant opportunities for Chinese companies, with a notable increase in the number of Chinese enterprises establishing production capacities abroad, reaching 229 in 2025, nearly doubling from 2024 [18] - ASEAN, Mexico, and India are the primary destinations for Chinese production capacity outflows, with ASEAN covering a wide range of industries [18] Group 5 - The AI expansion cycle is a core focus in the Chinese capital market, with significant growth expected in AI computing hardware, supported by macro investment scales and healthy balance sheets of major tech companies [29][30] - The capital expenditure of major cloud service providers is projected to increase significantly, reflecting strong demand for AI computing [35] Group 6 - Cultural and technological value output is becoming a major trend for Chinese enterprises going abroad, with significant growth in IP exports and innovative products in sectors like gaming and new dining [39][41] - The Chinese innovative pharmaceutical sector is increasingly integrated into the global supply chain, with more products commercialized in the US and Europe [41] Group 7 - Key sectors with strong overseas expansion opportunities in 2026 include new energy (batteries, grid equipment), machinery, TMT (technology, media, telecommunications), and innovative pharmaceuticals [46] - The gaming industry is also highlighted for its potential, with significant overseas revenue growth expected [49]

本文源自：金融界AI电报 据香港交易所披露，摩根大通对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2026年2 月12日从7.55%增至8.29%。 ...

该行料其2024至2027年的盈利年均复合增长率达24%，看好其独特的CRDMO/CTDMO模式及平台优 势，加上在中国竞争对手中拥有最多的早期项目数量，相较国内同业而言，为其中长期增长提供更强的 可见性。 智通财经APP获悉，摩根士丹利发布研报称，予药明康德(02359)"增持"评级，鉴于公司早前披露的2025 年初步业绩，因其毛利率上升，将其2026至2030年的盈利预测上调0%至3%，目标价因而由143港元升 至143.5港元。 ...

智通财经APP获悉，截止2月20日收盘，东北电气(00042)、京城机电股份(00187)、弘业期货(03678)分列 AH溢价率前三位，溢价率分别为800.00%、294.26%、292.86%；宁德时代(03750)、药明康德(02359)、 招商银行(03968)分列AH溢价率末三位，溢价率分别为-15.74%、-5.50%、-3.71%。其中京城机电股份 (00187)、剑桥科技(06166)、弘业期货(03678)的偏离值位居前三，分别为23.37%、23.34%、22.07%；另 外，晨鸣纸业(01812)、中海油田服务(02883)、钧达股份(02865)的偏离值位居后三，分别 为-59.49%、-29.71%、-25.40%。 | 凯盛新能(01108) | | | | | | --- | --- | --- | --- | --- | | 南华期货股份 | 10.200 | 18.34 | 115.39% | 16.88% | | (02691) | | | | | | 泰格医药(03347) | 48.800 | 64.4 | 58.07% | 13.30% | | 中州证券(01375) ...